Nikhil Anand, MD
Ophthalmology · Atlanta, GANPI 1972921427
Payments from drug & device makers
Across 344 payments — averaging $38.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- AbbVie$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Bausch & Lomb Americas Inc.$1K
- Sun Pharmaceutical Industries Inc.$918
- Harrow Eye, LLC$779
- plus $4K from 25 others
What the payments were for
- Food & beverage$13,150100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 67 | $4,100 |
| AbbVie(2 entities) | 50 | $1,649 |
| Johnson & Johnson Surgical Vision, Inc. | 24 | $1,093 |
| Bausch & Lomb Americas Inc. | 62 | $1,026 |
| Sun Pharmaceutical Industries Inc. | 16 | $918 |
| Harrow Eye, LLC | 22 | $779 |
| Glaukos Corporation | 6 | $654 |
| Oyster Point Pharma, Inc. | 18 | $492 |
| Ivantis, Inc | 3 | $329 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $326 |
| Carl Zeiss Meditec USA, Inc. | 2 | $223 |
| Novartis | 21 | $212 |
| Eyevance Pharmaceuticals LLC | 4 | $175 |
| Sight Sciences, Inc. | 3 | $173 |
| Rxsight Inc | 3 | $171 |
| Tarsus Pharmaceuticals, Inc. | 6 | $165 |
| Amgen(2 entities) | 4 | $153 |
| AstraZeneca | 2 | $124 |
| Astellas Pharma US Inc | 2 | $57 |
| Beaver-visitec International, Inc. | 1 | $56 |
| Mallinckrodt Hospital Products Inc. | 2 | $48 |
| Boston Scientific | 1 | $36 |
| Dompe US, Inc. | 2 | $35 |
| Baxter Healthcare | 1 | $24 |
| Thea Pharma Inc. | 1 | $24 |
| Lensar, Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Leadiant Biosciences, Inc. | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
| Medline Industries LP | 1 | $16 |
| Tearlab Corp | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$768
- CEQUA$643
- LenSx$641
- Hydrus Microstent$616
- CATALYS SYSTEM$277
- TYRVAYA$261
- iDoseTR$253
- MIEBO$233
- DURYSTA$220
- XELPROS$167
- Flarex$160
- IHEEZO$160
- Verkazia$160
- Tobradex ST$160
- Natacyn$160
- ARGOS$154
- XEN GLAUCOMA TREATMENT SYSTEM$149
- QUATERA 700$148
- Tecnis Simplicity$147
- Rocklatan$140
How this compares
$13,150 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 67 | $74,716 |
| RestasisCyclosporine | 69 | $65,017 |
| LumiganBimatoprost | 51 | $33,896 |
| TyrvayaVarenicline Tartrate | 14 | $12,398 |
| Cyclosporine | 20 | $10,819 |
| VyzultaLatanoprostene Bunod | 25 | $9,409 |
| Prednisolone Acetate | 155 | $7,308 |
| Travoprost | 40 | $6,132 |
| Latanoprost | 376 | $6,123 |
| Fluorometholone | 48 | $3,886 |
| Timolol Maleate | 213 | $2,981 |
| Brimonidine Tartrate | 78 | $2,890 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 116 | $2,538 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $2,357 |
| ValacyclovirValacyclovir Hcl | 17 | $1,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $1,649 | $98,913120 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,026 | $84,12492 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $492 | $12,39814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Atlanta
- Douglas DayAtlanta$1.1M
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Atul SharmaAtlanta$193K
- Chris BergstromAtlanta$139K
- Anastasios CostaridesAtlanta$137K
- Evan SchoenbergAtlanta$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.